Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NN-101
- Development stage
- Preclinical
- Lead developer
- NanoNewron
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NN-101 is a humanized single-domain camelid antibody (nanobody) developed by NanoNewron as part of its NewroBus platform technology. It is specifically engineered to target the transferrin receptor 1 (TfR1) expressed on brain endothelial cells, facilitating the transport of therapeutic biologics across the blood-brain barrier (BBB) through receptor-mediated transcytosis. Unlike some other TfR1-targeting agents, NN-101 is designed to bind to a site that does not compete with endogenous transferrin, thereby reducing the risk of hematological toxicity and interference with iron metabolism. Licensed from Rutgers University, this platform is intended to serve as a modular shuttle for delivering various payloads, such as enzymes or other antibodies, into the central nervous system to treat a range of neurodegenerative and CNS diseases. It is currently in the preclinical stage of development.
- Other names
- NewroBus
02
Targets
TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on NN-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NN-101.